Inhaled Treprostinil

Phase 3

Inhaled Treprostinil is one of 41 therapeutic programs targeting Progressive Pulmonary Fibrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Progressive Pulmonary FibrosisRecruiting

Idiopathic Pulmonary FibrosisEnrolling by invitation

COPD (chronic Obstructive Pulmonary Disease)Recruiting

Progressive Pulmonary FibrosisPhase 3

Recruiting

Idiopathic Pulmonary FibrosisPhase 3

Enrolling by invitation

COPD (chronic Obstructive Pulmonary Disease)Phase 2

Recruiting

Competition

Competitive Landscape

46 competitors in Idiopathic Pulmonary Fibrosis

#DrugCompanyPhaseTrials

Esbriet

LLegacy Health System

Approved

20 2

Medrol

Pfizer

Approved

1 3

Viagra

VViatris Specialty LLC

Approved

6 4

Remodulin

United Therapeutics

Approved

—5

Rapamune

PPrism Pharmaceuticals

Approved

1 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Qvar

Acetadote

AArbor Pharmaceuticals, Inc.

Rayos

Proair HFA

GGlaxo Dba Glaxosmithkline

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

COPD (chronic Obstructive Pulmonary Disease)

NCT07037836

Q4 2027

Phase 3Recruiting

Progressive Pulmonary Fibrosis

NCT05943535

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis1 trial

An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)

Enrolling by invitation· United Therapeutics logo

United Therapeutics·Phase 3·NCT04905693·1,850 enrolled

COPD (Chronic Obstructive Pulmonary Disease)1 trial

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

Recruiting·BBastiaan Driehuys·Phase 2·NCT07037836·10 enrolled

Progressive Pulmonary Fibrosis1 trial

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Recruiting· United Therapeutics logo

United Therapeutics·Phase 3·NCT05943535·698 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Inhaled Treprostinil. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Inhaled Treprostinil. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — United Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: United Therapeutics

Inhaled Treprostinil

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis1 trial

COPD (Chronic Obstructive Pulmonary Disease)1 trial

Progressive Pulmonary Fibrosis1 trial

References

Drug Info

Quick Facts

Related News